TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16482084

Group type: EXPERIMENTAL
Intervention: 1 mg of 17‐beta estradiol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12904894

Group type: EXPERIMENTAL
Intervention: Eniluracil (20 mg orally twice daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Eniluracil (8 and 7 days prior to surgery)
Number of subjects: 23
Study: 10828236

Group type: EXPERIMENTAL
Intervention: Duplex scan
Number of subjects: 103

Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 103
Study: 9356001

Group type: EXPERIMENTAL
Intervention: Aerosolized surfactant (palmitoylphosphadidylcholine [DPPC]) 607.5 mg/d for 2 weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 87
Study: 8472446

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression (ASD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open acromioplasty according to Neer
Number of subjects: 20
Study: 3485390

Group type: EXPERIMENTAL
Intervention: Lidocaine, 1 mg/kg intravenously 5 min before aortic unclamping and cardiac reperfusion, followed by infusion at 40 micrograms X kg‐1 X min‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 31924544

Group type: EXPERIMENTAL
Intervention: OPT-302 monotherapy (2 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: OPT-302 (2 mg) combined with ranibizumab (0.5 mg)
Number of subjects: 51
Study: 29633644

Group type: EXPERIMENTAL
Intervention: KT‐11 food tablet (1.2×10^10 KT‐11 cells)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo food tablet (without KT‐11)
Number of subjects: 16
Study: 28689898

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisone (10 mg/day to 60 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisone (35 mg/day)
Number of subjects: 0
Study: 25138758

Group type: EXPERIMENTAL
Intervention: 20% cord blood serum (CBS)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 20% autologous serum (ALS)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Preservative-free artificial tear (AT) drops
Number of subjects: 144
Study: 23334732

Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg weekly) plus exercise (using ARED)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Exercise using ARED
Number of subjects: 7

Group type: COMPARATOR
Intervention: Exercise using the interim resistance exercise device
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combination of exercise plus antiresorptive drug (alendronate)
Number of subjects: 7
Study: 22008228

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MTCP) 20 mg IV
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) 50 mg IV
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 26
Study: 19037043

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology
Number of subjects: 89784
Study: 16612587

Group type: EXPERIMENTAL
Intervention: Abnormal (123)I‐MIBG uptake in IVF patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Normal (123)I‐MIBG uptake in IVF patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sympathetic innervation impairment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (medullary carcinoma patients)
Number of subjects: 20
Study: 14525751

Group type: EXPERIMENTAL
Intervention: High-viscosity octylcyanoacrylate (OCA) tissue adhesive
Number of subjects: 84

Group type: COMPARATOR
Intervention: Low-viscosity octylcyanoacrylate (OCA) tissue adhesive
Number of subjects: 84
Study: 10824361

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simvastatin and low-fat diet
Number of subjects: 60
Study: 8866496

Group type: EXPERIMENTAL
Intervention: Idebenone (antioxidant and enhancer of oxidative metabolism)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1473740

Group type: EXPERIMENTAL
Intervention: Combination chlorambucil and cisplatin
Number of subjects: 369

Group type: COMPARATOR
Intervention: Sequential chlorambucil followed by cisplatin on treatment failure
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Invasive cancer with residuum less than 2 cm after initial surgery
Number of subjects: 369

Group type: COMPARATOR
Intervention: Invasive cancer with more tumor residuum
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Complete clinical response
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Complete surgical response
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Tumors of low malignant potential
Number of subjects: 369
Study: 6424041

Group type: COMPARATOR
Intervention: Phenobarbital (PH)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sodium Valproate (SV)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (PO)
Number of subjects: 69
Study: 31532902

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir (DRV/r) plus raltegravir (RAL)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir (DRV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Number of subjects: 201
Study: 29730918

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Ginseng Rg3
Number of subjects: 414

Group type: COMPARATOR
Intervention: Chemotherapy combined with placebo
Number of subjects: 414
Study: 27114413

Group type: EXPERIMENTAL
Intervention: Preoperative dexamethasone (0.15 mg/kg before ESD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Postoperative dexamethasone (placebo before ESD, dexamethasone after ESD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preoperative dexamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Postoperative dexamethasone
Number of subjects: 40
Study: 25203167

Group type: EXPERIMENTAL
Intervention: Active stimulation (low-frequency rTMS over the right orbitofrontal cortex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 23015655

Group type: EXPERIMENTAL
Intervention: tesamorelin, 2 mg once daily for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 20806768

Group type: EXPERIMENTAL
Intervention: Tourniquet (Group T)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 30
Study: 17331931

Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 450

Group type: COMPARATOR
Intervention: Transdermal diclofenac patch
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo patch (Control)
Number of subjects: 450
Study: 16361616

Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m2/3 h, carboplatin (AUC = 6), tirapazamine 260 mg/m2 (escalated to 330 mg/m2 in cycle 2 if tolerable)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin (no tirapazamine)
Number of subjects: 367
Study: 12013693

Group type: EXPERIMENTAL
Intervention: 3D reconstruction
Number of subjects: 81

Group type: COMPARATOR
Intervention: 2D presentations
Number of subjects: 81
Study: 11532465

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel (LNG/EE)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 9468459

Group type: EXPERIMENTAL
Intervention: Diuretic (hydrochlorothiazide plus triamterene)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitor (trandolapril)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Calcium antagonist (amlodipine, added after 3 months if required)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (during run-in period)
Number of subjects: 27
Study: 8181121

Group type: EXPERIMENTAL
Intervention: h-SOD (10 mg/kg intravenous bolus followed by 0.2 mg.kg-1.min-1 infusion)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 3310630

Group type: EXPERIMENTAL
Intervention: Sucralfate suspension (n = 31)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (n = 37)
Number of subjects: 68
Study: 31670998

Group type: EXPERIMENTAL
Intervention: 17α-hydroxyprogesterone caproate (250 mg/IM weekly until 37 weeks' gestation)
Number of subjects: 114
Study: 29630639

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 29
Study: 27163358

Group type: COMPARATOR
Intervention: Bicycle exercise with pancreatic clamp
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Bicycle exercise without pancreatic clamp
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Bicycle exercise in patients with T2D
Number of subjects: 2
Study: 25669920

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus helveticus and Lactobacillus rhamnosus) low-dose (4 × 10(9) CFU/day)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus helveticus and Lactobacillus rhamnosus) high-dose (8 × 10(9) CFU/day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 23889923

Group type: EXPERIMENTAL
Intervention: Oral prednisone as an add-on therapy to verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy with verapamil
Number of subjects: 0
Study: 20946690

Group type: EXPERIMENTAL
Intervention: Telephone hotline intervention for postpartum support accessed for the first four months after delivery
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Telephone hotline intervention with algorithms developed by the study team
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Questions related to mothers
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Questions related to infants
Number of subjects: 353
Study: 18958776

Group type: EXPERIMENTAL
Intervention: Tailored print communications delivered by mail (N = 288)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Nontailored print communications delivered by mail (N = 288)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Summer intervention materials (N = 288)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Control group (N = 311)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Greater program exposure/engagement
Number of subjects: 599
Study: 16231168

Group type: EXPERIMENTAL
Intervention: DHEA (150 mg b.d. for 7 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12791812

Group type: COMPARATOR
Intervention: (123)I‐beta‐CIT SPECT
Number of subjects: 45

Group type: COMPARATOR
Intervention: Striatal V(3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Midbrain outcome measures in PD patients with depression
Number of subjects: 45
Study: 10654060

Group type: COMPARATOR
Intervention: Standard rehabilitation program
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Standard program augmented with a perturbation training program
Number of subjects: 26
Study: 8711640

Group type: EXPERIMENTAL
Intervention: rhDNase 2.5 mg twice daily for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1506213

Group type: EXPERIMENTAL
Intervention: Coal tar preparation applied twice weekly for 8 weeks (mode I)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Coal tar preparation applied daily for 8 weeks (mode II)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Coal tar preparation used under occlusion for 30 min every second day for 4 weeks (mode III)
Number of subjects: 15
Study: 31006669

Group type: EXPERIMENTAL
Intervention: Mean platelet volume (MPV) levels above 11 fL
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: NT-pro-BNP levels above 125 pg/ml, thrombocytopenia, atrial fibrillation/flutter
Number of subjects: 658

Group type: COMPARATOR
Intervention: MPV values
Number of subjects: 658
Study: 29471988

Group type: EXPERIMENTAL
Intervention: Paclitaxel-Coated Balloon (PCB) Angioplasty
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional Balloon Angioplasty (PTA)
Number of subjects: 64
Study: 26431684

Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Food-related EFT
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (recalling episodic past events)
Number of subjects: 94
Study: 25234015

Group type: EXPERIMENTAL
Intervention: Prednisolone acetate 1% eye drops 4 times per day for 5 days after SLT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5% eye drops 4 times per day for 5 days after SLT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 0
Study: 21740467

Group type: COMPARATOR
Intervention: Diet with 12% fat
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Diet with 26% fat
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Diet with 40% fat
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Diet with 54% fat
Number of subjects: 64
Study: 20202002

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg/day) for a maximum of 4 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg/day)
Number of subjects: 71
Study: 17703640

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg daily
Number of subjects: 12092

Group type: COMPARATOR
Intervention: Usual care / Unfractionated heparin
Number of subjects: 12092
Study: 16385658

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5 mg/kg before the induction of anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study: 11959735

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 200
Study: 9708713

Group type: EXPERIMENTAL
Intervention: Homeopathic remedy (Vertigoheel)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Betahistine hydrochloride (active control)
Number of subjects: 119
Study: 7609169

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alarm therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 50
Study: 2227172

Group type: EXPERIMENTAL
Intervention: Stress management program provided by a nurse including one to three teaching sessions, reading material, audiotapes, and telephone follow‐up.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Stress management program (experimental group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study: 91483

Group type: EXPERIMENTAL
Intervention: THC 180-210 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: THC 70-90 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 31120313

Group type: EXPERIMENTAL
Intervention: 10% lidocaine ointment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 25
Study: 28148473

Group type: EXPERIMENTAL
Intervention: PedAMINES
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional preparation methods
Number of subjects: 20
Study: 26455190

Group type: EXPERIMENTAL
Intervention: TXA (10 mg/kg) injected intravenously approximately 10 minutes before tourniquet release
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TXA group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 23355148

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose 1 μg kg(‐1) over 10 min, followed by constant intravenous infusion 0.7 μg kg(‐1) h(‐1))
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 50
Study: 21393261

Group type: EXPERIMENTAL
Intervention: Ultrasound and colour Doppler-guided sclerosing polidocanol injections
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ultrasound and colour Doppler-guided arthroscopic shaving
Number of subjects: 52
Study: 19726302

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 53

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 53
Study: 17853766

Group type: EXPERIMENTAL
Intervention: Needling method for regulating wei and strengthening brain
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal needling method (control group)
Number of subjects: 200
Study: 15082493

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Rheumatic diagnosis
Number of subjects: 64
Study: 11319482

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (trivalent subvirion vaccine, 15mg of surface antigens)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 344

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 344
Study: 9141738

Group type: EXPERIMENTAL
Intervention: Telephone prompt by a medical researcher (Group A)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Telephone prompt by a nonmedical research assistant (Group B)
Number of subjects: 373
Study: 7951402

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol, 50 micrograms/day (Estraderm TTS 50) for 14 days, followed by transdermal combination of 17 beta‐estradiol (50 micrograms/day) and norethisterone acetate (NETA) 250 micrograms/day for the next 14 days (Group A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol, 50 micrograms/day (Estraderm TTS 50) for 28 days, adding oral medroxyprogesterone acetate (MPA), 10 mg/day, during the final 14 days (Group B)
Number of subjects: 21
Study: 3299565

Group type: EXPERIMENTAL
Intervention: Ambroxol 120 mg daily
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ambroxol 60 mg daily
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 31012984

Group type: EXPERIMENTAL
Intervention: GLPG1690 single doses (20, 60, 150, 300, 600, 1000, 1500 mg)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: GLPG1690 multiple doses (150 mg twice daily for 14 days; 600 and 1000 mg once daily)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: GLPG1690 600 mg (tablet vs capsule)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: GLPG1690 (various doses)
Number of subjects: 53

Group type: COMPARATOR
Intervention: GLPG1690 (tablet formulation)
Number of subjects: 53
Study: 27901329

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 46

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 46
Study: 25474337

Group type: EXPERIMENTAL
Intervention: Drop Sets (DS)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Flywheel (FW)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Plyometrics (PL)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Maximal Voluntary Isometric Contraction (MVIC)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: TMG measurements of maximal radial displacement of the muscle belly (Dm)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Contraction time between 10 and 90% of Dm (Tc)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mean muscle contraction velocities from the beginning until 10% (V10) and 90% of Dm (V90)
Number of subjects: 14
Study: 22759088

Group type: EXPERIMENTAL
Intervention: Pregabalin treatment for 40 days
Number of subjects: 99
Study: 20655703

Group type: EXPERIMENTAL
Intervention: Tongue trills (EG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo exercises (CG)
Number of subjects: 37
Study: 19751459

Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) + Olmesartan Medoxomil (OM) 5+40 mg/d
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) + Olmesartan Medoxomil (OM) 10+40 mg/d
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) + Olmesartan Medoxomil (OM) + Hydrochlorothiazide (HCTZ) 10+40+12.5 mg/d
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) + Olmesartan Medoxomil (OM) + Hydrochlorothiazide (HCTZ) 10+40+25 mg/d
Number of subjects: 1684
Study: 17456720

Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 339
Study: 15172210

Group type: EXPERIMENTAL
Intervention: 45 min light exposure to 10,000 lux for 60 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 min light exposure to 10,000 lux for 60 days
Number of subjects: 0
Study: 11223704

Group type: EXPERIMENTAL
Intervention: Preeclamptic women in labor
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normotensive pregnant controls in labor
Number of subjects: 38
Study: 9741068

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8277066

Group type: EXPERIMENTAL
Intervention: Intravenous anistreplase (30 U) given at home
Number of subjects: 311

Group type: COMPARATOR
Intervention: Intravenous anistreplase (30 U) given in the hospital
Number of subjects: 311
Study: 2929440

Group type: EXPERIMENTAL
Intervention: Rate-adaptive pacemakers (various types)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Activity-sensing pacemakers (Activitrax and Sensolog)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Respiratory-sensing pacemakers (Biorate and Meta)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All pacemakers studied
Number of subjects: 46

Group type: COMPARATOR
Intervention: Constant-rate ventricular pacing (VVI)
Number of subjects: 46
Study: 27992296

Group type: EXPERIMENTAL
Intervention: Sling exercise with elastic bands
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional trunk-muscle-stabilizing exercise
Number of subjects: 0
Study: 26370515

Group type: EXPERIMENTAL
Intervention: Drug Coated Balloon (DCB) angioplasty
Number of subjects: 120

Group type: COMPARATOR
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both DCB and DES
Number of subjects: 120